Epidermal growth factor receptor: a promising target in solid tumours - PubMed

Review

Epidermal growth factor receptor: a promising target in solid tumours

Janessa J Laskin et al. Cancer Treat Rev. 2004 Feb.

Abstract

The epidermal growth factor receptor (EGFR) is expressed in a wide variety of solid tumours. It has been demonstrated that the EGFR-associated signaling pathway plays an important role in carcinogenesis and cancer progression. In the new therapeutic paradigm of molecular-targeted cancer therapy, interference with intracellular signaling cascades is an appealing treatment approach. Inhibitory strategies under study include monoclonal antibodies, tyrosine kinase inhibitors, EGFR-ligand conjugates, EGFR immunoconjugates, and antisense oligonucleotides. Many of these strategies have demonstrated efficacy against EGFR-expressing tumour cells in preclinical studies, prompting a large number of clinical trials. In particular, clinical studies using monoclonal antibody blockade and EGFR tyrosine kinase inhibitors have suggested that EGFR blockade is a well-tolerated and effective treatment strategy; however, more trials are needed to precisely define how these agents will fit into modern cancer care.

Similar articles

• Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective.

  Raben D, Helfrich B, Bunn PA Jr. Raben D, et al. Int J Radiat Oncol Biol Phys. 2004;59(2 Suppl):27-38. doi: 10.1016/j.ijrobp.2004.01.054. Int J Radiat Oncol Biol Phys. 2004. PMID: 15142632 Review.

• Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.

  Tortora G, Ciardiello F, Gasparini G. Tortora G, et al. Nat Clin Pract Oncol. 2008 Sep;5(9):521-30. doi: 10.1038/ncponc1161. Epub 2008 Jul 1. Nat Clin Pract Oncol. 2008. PMID: 18594498 Review.

• Rational bases for the development of EGFR inhibitors for cancer treatment.

  Bianco R, Gelardi T, Damiano V, Ciardiello F, Tortora G. Bianco R, et al. Int J Biochem Cell Biol. 2007;39(7-8):1416-31. doi: 10.1016/j.biocel.2007.05.008. Epub 2007 May 21. Int J Biochem Cell Biol. 2007. PMID: 17596994 Review.

• EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.

  Dassonville O, Bozec A, Fischel JL, Milano G. Dassonville O, et al. Crit Rev Oncol Hematol. 2007 Apr;62(1):53-61. doi: 10.1016/j.critrevonc.2006.12.008. Epub 2007 Feb 26. Crit Rev Oncol Hematol. 2007. PMID: 17324578 Review.

Cited by

• Hydrogel-based protein array for quantifying epidermal growth factor receptor activity in cell lysates.

  Ghosh G, Lee AG, Palecek SP. Ghosh G, et al. Anal Biochem. 2009 Oct 15;393(2):205-14. doi: 10.1016/j.ab.2009.07.002. Epub 2009 Jul 5. Anal Biochem. 2009. PMID: 19583965 Free PMC article.

• Current molecular imaging positron emitting radiotracers in oncology.

  Zhu A, Shim H. Zhu A, et al. Nucl Med Mol Imaging. 2011 Mar;45(1):1-14. doi: 10.1007/s13139-011-0075-y. Epub 2011 Feb 1. Nucl Med Mol Imaging. 2011. PMID: 24899972 Free PMC article. Review.

• P42 Ebp1 functions as a tumor suppressor in non-small cell lung cancer.

  Ko HR, Nguyen TL, Kim CK, Park Y, Lee KH, Ahn JY. Ko HR, et al. BMB Rep. 2015 Mar;48(3):159-65. doi: 10.5483/bmbrep.2015.48.3.130. BMB Rep. 2015. PMID: 24998263 Free PMC article.

• Novel EGFR-targeted strategy with hybrid peptide against oesophageal squamous cell carcinoma.

  Kikuchi O, Ohashi S, Horibe T, Kohno M, Nakai Y, Miyamoto S, Chiba T, Muto M, Kawakami K. Kikuchi O, et al. Sci Rep. 2016 Mar 9;6:22452. doi: 10.1038/srep22452. Sci Rep. 2016. PMID: 26956916 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal